Biological therapy in hereditary angioedema: transformation of a rare disease

References

• Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet. 2012 Feb 4;379(9814):474–481. PubMed PMID: 22305226.
   PubMed Web of Science ®Google Scholar
• Longhurst HJ, Bork K. Hereditary angioedema: an update on causes, manifestations and treatment. Br J Hosp Med (Lond). 2019 July 2;80(7):391–398. PubMed PMID: 31283393.
   PubMed Web of Science ®Google Scholar
• Longhurst H, Bygum A. The humanistic, societal, and pharmaco-economic burden of angioedema. Clin Rev Allergy Immunol. 2016 Oct;51(2):230–239. PubMed PMID: 27388236.
   PubMed Web of Science ®Google Scholar
• Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol. 2012 Sept;130(3):692–697. PubMed PMID: 22841766.
   PubMed Web of Science ®Google Scholar
• Bork K, Meng G, Staubach P, et al. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion. 2005 Nov;45(11):1774–1784. PubMed PMID: 16271103.
   PubMed Web of Science ®Google Scholar
• Bork K, Staubach P, Eckardt AJ, et al. Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency. Am J Gastroenterol. 2006 Mar;101(3):619–627. PubMed PMID: 16464219.
   PubMed Web of Science ®Google Scholar
• Farkas H, Harmat G, Kaposi PN, et al. Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema. Eur J Gastroenterol Hepatol. 2001 Oct;13(10):1225–1230. PubMed PMID: 11711780.
   PubMed Web of Science ®Google Scholar
• Ponard D, Gaboriaud C, Charignon D, et al. SERPING1 mutation update: mutation spectrum and C1 Inhibitor phenotypes. Hum Mutat. 2019 Sep 13. DOI:10.1002/humu.23917. PubMed PMID: 31517426.
   PubMed Web of Science ®Google Scholar
• Germenis AE, Speletas M. Genetics of hereditary angioedema revisited. Clin Rev Allergy Immunol. 2016 Oct;51(2):170–182. PubMed PMID: 27116602.
   PubMed Web of Science ®Google Scholar
• Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun. 2006 May 19;343(4):1286–1289. PubMed PMID: 16638441.
   PubMed Web of Science ®Google Scholar
• Bork K, Wulff K, Steinmuller-Magin L, et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy. 2018 Feb;73(2):442–450. PubMed PMID: 28795768.
   PubMed Web of Science ®Google Scholar
• Bafunno V, Firinu D, D’Apolito M, et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol. 2018 Mar;141(3):1009–1017. PubMed PMID: 28601681.
   PubMed Web of Science ®Google Scholar
• Bork K, Wulff K, Rossmann H, et al. Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin. Allergy. 2019 May 14;74:2479–2481. PubMed PMID: 31087670.
   Google Scholar
• Bork K. Hereditary angioedema with normal c1 inhibition. Curr Allergy Asthma Rep. 2009 Jul;9(4):280–285. PubMed PMID: 19656474.
   PubMed Web of Science ®Google Scholar
• Veronez CL, Moreno AS, Constantino-Silva RN, et al. Hereditary angioedema with normal C1 inhibitor and F12 mutations in 42 Brazilian families. J Allergy Clin Immunol Pract. 2018 Jul - Aug;6(4):1209–1216 e8. PubMed PMID: 29128335.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Bergamaschini L, Marasini B, et al. Hereditary angioedema: an appraisal of 104 cases. Am J Med Sci. 1982 Jul-Aug;284(1):2–9. PubMed PMID: 7091182.
   PubMed Web of Science ®Google Scholar
• Farkas H. Management of upper airway edema caused by hereditary angioedema. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):19. PubMed PMID: 20667122; PubMed Central PMCID: PMCPMC2920238.
   PubMedGoogle Scholar
• Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010 Sep-Oct;31(5):407–414. PubMed PMID: 20929608.
   PubMed Web of Science ®Google Scholar
• Aygoren-Pursun E, Bygum A, Beusterien K, et al. Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J Rare Dis. 2014 Jul 4;9:99. PubMed PMID: 24996814; PubMed Central PMCID: PMCPMC4105891.
   PubMed Web of Science ®Google Scholar
• Aygoren-Pursun E, Bygum A, Beusterien K, et al. Estimation of EuroQol 5-dimensions health status utility values in hereditary angioedema. Patient Prefer Adherence. 2016;10:1699–1707. . PubMed PMID: 27660419; PubMed Central PMCID: PMCPMC5019462.
   PubMed Web of Science ®Google Scholar
• Nordenfelt P, Dawson S, Wahlgren CF, et al. Quantifying the burden of disease and perceived health state in patients with hereditary angioedema in Sweden. Allergy Asthma Proc. 2014 Mar-Apr;35(2):185–190. PubMed PMID: 24411585.
   PubMed Web of Science ®Google Scholar
• Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2017 revision and update. Allergy. 2018 Aug;73(8):1575–1596. PubMed PMID: 29318628.
   PubMed Web of Science ®Google Scholar
• Donaldson VH, Rosen FS. Action of complement in hereditary angioneurotic edema: the role of C’1-esterase. J Clin Invest. 1964 Nov;43:2204–2213. PubMed PMID: 14223932; PubMed Central PMCID: PMCPMC442008.
   PubMed Web of Science ®Google Scholar
• Rosen FS, Pensky J, Donaldson V, et al. Hereditary angioneurotic edema: two genetic variants. Science. 1965 May 14;148(3672):957–958. PubMed PMID: 14277836.
   PubMed Web of Science ®Google Scholar
• Pickering RJ, Good RA, Kelly JR, et al. Replacement therapy in hereditary angioedema. Successful treatment of two patients with fresh frozen plasma. Lancet. 1969 Feb 15;1(7590):326–330. PubMed PMID: 4179348.
   PubMed Web of Science ®Google Scholar
• Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol. 2007 Apr;98(4):383–388. PubMed PMID: 17458436.
   PubMed Web of Science ®Google Scholar
• Brackertz D, Kueppers F. Hereditary angioneurotic oedema. Lancet. 1973 Sept 22;2(7830):680. PubMed PMID: 4125654.
   PubMed Web of Science ®Google Scholar
• Waytes AT, Rosen FS, Frank MM. Treatment of hereditary angioedema with a vapor-heated C1 inhibitor concentrate. N Engl J Med. 1996 Jun 20;334(25):1630–1634. PubMed PMID: 8628358.
   PubMed Web of Science ®Google Scholar
• Kunschak M, Engl W, Maritsch F, et al. A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion. 1998 Jun;38(6):540–549. PubMed PMID: 9661687.
   PubMed Web of Science ®Google Scholar
• Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009 Oct;124(4):801–808. PubMed PMID: 19767078.
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):513–522. PubMed PMID: 20818886.
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med. 2012 Sep;125(9):938 e1–7. PubMed PMID: 22800873.
   PubMed Web of Science ®Google Scholar
• Craig TJ, Rojavin MA, Machnig T, et al. Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2013 Sep;111(3):211–215. PubMed PMID: 23987198.
   PubMed Web of Science ®Google Scholar
• Farkas H, Martinez-Saguer I, Bork K, et al. International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency. Allergy. 2017 Feb;72(2):300–313. PubMed PMID: 27503784; PubMed Central PMCID: PMCPMC5248622.
   PubMed Web of Science ®Google Scholar
• Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012 Feb;129(2):308–320. PubMed PMID: 22197274.
   PubMed Web of Science ®Google Scholar
• Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):22. PubMed PMID: 20667125; PubMed Central PMCID: PMCPMC2922091.
   PubMedGoogle Scholar
• Otani IM, Lumry WR, Hurwitz S, et al. Subcutaneous icatibant for the treatment of hereditary angioedema attacks: comparison of home self-administration with administration at a medical facility. J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2):442–447 e1. PubMed PMID: 27818136.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Mannucci PM, Castelli R, et al. Reduction in transmission of hepatitis C after the introduction of a heat-treatment step in the production of C1-inhibitor concentrate. Transfusion. 1995 Mar;35(3):209–212. PubMed PMID: 7878712.
   PubMed Web of Science ®Google Scholar
• De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. [email protected]. Transfus Apher Sci. 2003 Dec;29(3):247–254. PubMed PMID: 14572817.
   PubMed Web of Science ®Google Scholar
• Terpstra FG, Kleijn M, Koenderman AH, et al. Viral safety of C1-inhibitor NF. Biologicals. 2007 Jun;35(3):173–181. PubMed PMID: 17071103.
   PubMed Web of Science ®Google Scholar
• Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States food and drug administration adverse event reporting system database. Pharmacotherapy. 2012 Oct;32(10):902–909. PubMed PMID: 23033229.
   PubMed Web of Science ®Google Scholar
• Kalaria S, Craig T. Assessment of hereditary angioedema treatment risks. Allergy Asthma Proc. 2013 Nov-Dec;34(6):519–522. PubMed PMID: 24169059.
   PubMed Web of Science ®Google Scholar
• Farkas H, Kohalmi KV, Veszeli N, et al. Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor. Allergy Asthma Proc. 2016 Mar-Apr;37(2):164–170. PubMed PMID: 26802388.
   PubMed Web of Science ®Google Scholar
• van Doorn MB, Burggraaf J, van Dam T, et al. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. J Allergy Clin Immunol. 2005 Oct;116(4):876–883. PubMed PMID: 16210064.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Relan A, Harper JR, et al. Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2017 Apr;118(4):452–455. PubMed PMID: 28284978.
   PubMed Web of Science ®Google Scholar
• Farkas H, Varga L, Moldovan D, et al. Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor. Ann Allergy Asthma Immunol. 2016 Nov;117(5):508–513. PubMed PMID: 27788880.
   PubMed Web of Science ®Google Scholar
• Hack CE, Relan A, Baboeram A, et al. Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of IgE antibodies. Clin Drug Investig. 2013 Apr;33(4):275–281. PubMed PMID: 23463274.
   PubMed Web of Science ®Google Scholar
• Hack CE, Mannesse M, Baboeram A, et al. Immunogenicity assessment of recombinant human c1-inhibitor: an integrated analysis of clinical studies. BioDrugs. 2012 Oct 1;26(5):303–313. PubMed PMID: 22928662.
   PubMed Web of Science ®Google Scholar
• Hack CE, Relan A, van Amersfoort ES, et al. Target levels of functional C1-inhibitor in hereditary angioedema. Allergy. 2012 Jan;67(1):123–130. PubMed PMID: 21923668.
   PubMed Web of Science ®Google Scholar
• Feussner A, Kalina U, Hofmann P, et al. Biochemical comparison of four commercially available C1 esterase inhibitor concentrates for treatment of hereditary angioedema. Transfusion. 2014 Oct;54(10):2566–2573. PubMed PMID: 24805006; PubMed Central PMCID: PMCPMC4285325.
   PubMed Web of Science ®Google Scholar
• Maas C, Lopez-Lera A. Hereditary angioedema: insights into inflammation and allergy. Mol Immunol. 2019 Aug;112:378–386. PubMed PMID: 31279849.
   PubMed Web of Science ®Google Scholar
• Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011 Dec;107(6):529–537. PubMed PMID: 22123383.
   PubMed Web of Science ®Google Scholar
• Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010 Aug 5;363(6):532–541. PubMed PMID: 20818888; PubMed Central PMCID: PMCPMC4662377.
   PubMed Web of Science ®Google Scholar
• Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010 Jun;104(6):523–529. PubMed PMID: 20568386.
   PubMed Web of Science ®Google Scholar
• Sheffer AL, Campion M, Levy RJ, et al. Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies. J Allergy Clin Immunol. 2011 Jul;128(1):153–159 e4. PubMed PMID: 21481442.
   PubMed Web of Science ®Google Scholar
• Longhurst HJ, Aberer W, Bouillet L, et al. Analysis of characteristics associated with reinjection of icatibant: results from the icatibant outcome survey. Allergy Asthma Proc. 2015 Sep-Oct;36(5):399–406. PubMed PMID: 26314822.
   PubMed Web of Science ®Google Scholar
• Maurer M, Aberer W, Bouillet L, et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One. 2013;8(2):e53773. . PubMed PMID: 23390491; PubMed Central PMCID: PMCPMC3563637.
   PubMed Web of Science ®Google Scholar
• Martinez-Saguer I, Cicardi M, Suffritti C, et al. Pharmacokinetics of plasma-derived C1-esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION study. Transfusion. 2014 Jun;54(6):1552–1561. PubMed PMID: 24266596; PubMed Central PMCID: PMCPMC4215596.
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Cicardi M, Longhurst HJ, et al. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate. Allergy. 2015 Oct;70(10):1319–1328. PubMed PMID: 26016741; PubMed Central PMCID: PMCPMC4755045.
   PubMed Web of Science ®Google Scholar
• Longhurst H, Cicardi M, Craig T, et al. Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor. N Engl J Med. 2017 Mar 23;376(12):1131–1140. PubMed PMID: 28328347.
   PubMed Web of Science ®Google Scholar
• Craig T, Zuraw B, Longhurst H, et al. Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks. J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1793–1802 e2. PubMed PMID: 30772477.
   PubMed Web of Science ®Google Scholar
• Banerji A, Riedl MA, Bernstein JA, et al. Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial. JAMA. 2018 Nov 27;320(20):2108–2121. PubMed PMID: 30480729; PubMed Central PMCID: PMCPMC6583584.
   PubMed Web of Science ®Google Scholar
• Hwang JR, Hwang G, Johri A, et al. Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema. Immunotherapy. 2019 Oct 22. DOI:10.2217/imt-2019-0128. [ PubMed PMID: 31635497].
   Web of Science ®Google Scholar
• Ira Kalfus EO, McDonald. A. Pharmacokinetics, safety, and potency of ATN-249, a novel oral plasma kallikrein inhibitor for hereditary angioedema. Allergy, Asthma & Clin Immunol. 2019;15(Suppl 4):O26.
   Google Scholar
• Maetzel A, Smith MS, Duckworth EJ. KVD900, a new oral on-demand treatment of hereditary angioedema attacks achieves complete plasma kallikrein suppression: safety, tolerability, pharmacokinetic and pharmacodynamic results from a phase 1 first-in-human study. Allergy Asthma Clin Immunol. 2019;15(Suppl 4):O2.
   PubMedGoogle Scholar
• Aygoren-Pursun E, Bygum A, Grivcheva-Panovska V, et al. Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema. N Engl J Med. 2018 Jul 26;379(4):352–362. PubMed PMID: 30044938.
   PubMed Web of Science ®Google Scholar
• Stobiecki M, Aygören-Pürsün E, Andarawewa S. et al. Clinical evaluation of pharmacokinetics, pharmacodynamics, safety, and e cacy dose–response of BCX7353as an acute treatment for angioedema in patients with hereditary angioedema (HAE). Allergy, Asthma & Clin Immunol 2019, 15(Suppl 4):45 O24
   Google Scholar
• Vardi M, Girolami A, Sexton D, et al. Long-term safety outcomes of prekallikrein deficiency: a systematic literature review. J Allergy Clin Immunol. 2018;141:AB58.
   Web of Science ®Google Scholar
• Bhattacharjee G, Revenko AS, Crosby JR, et al. Inhibition of vascular permeability by antisense-mediated inhibition of plasma kallikrein and coagulation factor 12. Nucleic Acid Ther. 2013 Jun;23(3):175–187. PubMed PMID: 23582057.
   PubMed Web of Science ®Google Scholar
• Cao H, Biondo M, Lioe H, et al. Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation. J Allergy Clin Immunol. 2018 Oct;142(4):1355–1358. PubMed PMID: 29936101.
   PubMed Web of Science ®Google Scholar
• Liu JQJ and Cooley B. Reduction of hepatic factor XII expression in mice by ALN-F12 inhibits thrombosis without increasing bleeding risk 2017. [cited 2019 Oct 15]. Available from: http://www.alnylam.com/wpcontent/uploads/2017/07/ALN-F12-ISTH2017-Presentation-Final.pdf
   Google Scholar
• Liu J, Qin J, Borodovsky A, et al. An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema. RNA. 2019 Feb;25(2):255–263. PubMed PMID: 30463937; PubMed Central PMCID: PMCPMC6348991.
   PubMed Web of Science ®Google Scholar
• Melquist SWD, Hamilton H, Chu Q, et al. Targeting factor 12 (F12) with a novel RNAi delivery platform as a prophylactic treatment for Hereditary Angioedema (HAE). [cited 2019 Oct 15]. Available from: https://arrowheadpharma.com/pipeline/
   Google Scholar
• Marceau F, Lesage ASJ, Knolle J, et al. Pharmacological pro le of PHA‐022121, a non‐peptide bradykinin B2 receptor antagonist, established using the isolated human umbilical vein. Allergy, Asthma & ClinImmunol. 2019;15(Suppl 4):O19.
   Google Scholar
• Qiu T, Chiuchiolo MJ, Whaley AS, et al. Gene therapy for C1 esterase inhibitor deficiency in a murine model of hereditary angioedema. Allergy. 2019 Jun;74(6):1081–1089. PubMed PMID: 30059156; PubMed Central PMCID: PMCPMC6752709.
   PubMed Web of Science ®Google Scholar
• C1-INH deficiency and angioedema workshop [cited 2019 Oct 15]. Available from: http://www.2019.haenetworkshop.hu/
   Google Scholar
• HAE global conference 2020 [cited 2019 Oct 15]. Available from: https://haei.org/gc2020/
   Google Scholar
• Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an international working group. Allergy. 2012 Feb;67(2):147–157. PubMed PMID: 22126399.
   PubMed Web of Science ®Google Scholar
• Zuraw BL, Banerji A, Bernstein JA, et al. US hereditary angioedema association medical advisory board 2013 recommendations for the management of hereditary angioedema due to C1 inhibitor deficiency. J Allergy Clin Immunol Pract. 2013 Sep-Oct;1(5):458–467. PubMed PMID: 24565617.
   PubMed Web of Science ®Google Scholar
• Longhurst HJ, Tarzi MD, Ashworth F, et al. C1 inhibitor deficiency: 2014 United Kingdom consensus document. Clin Exp Immunol. 2015 June;180(3):475–483. PubMed PMID: 25605519; PubMed Central PMCID: PMCPMC4449776.
   PubMed Web of Science ®Google Scholar
• Betschel S, Badiou J, Binkley K, et al. Canadian hereditary angioedema guideline. Allergy Asthma Clin Immunol. 2014;10(1):50. PubMed PMID: 25352908; PubMed Central PMCID: PMCPMC4210625.
   PubMedGoogle Scholar
• [cited 2019 Nov 10]. Available from: https://www.england.nhs.uk/wp-content/uploads/2018/07/Plasma-derived-C1-esterase-inhibitor-for-prophylactic-treatment-of-hereditary-angioesema-types-I-and-II.pdf
   Google Scholar
• HAEiOrg Global Access Program. [cited 2019 Oct 15]. Available from: https://haei.org/resources/global_access_program/
   Google Scholar
• Joseph K, Bains S, Tholanikunnel BG, et al. A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin-forming enzymes. Allergy. 2015 Jan;70(1):115–119. PubMed PMID: 25186184.
   PubMed Web of Science ®Google Scholar
• Lara-Marquez ML, Christiansen SC, Riedl MA, et al. Threshold-stimulated kallikrein activity distinguishes bradykinin- from histamine-mediated angioedema. Clin Exp Allergy. 2018 Nov;48(11):1429–1438. PubMed PMID: 29957871.
   PubMed Web of Science ®Google Scholar
• Defendi F, Charignon D, Ghannam A, et al. Enzymatic assays for the diagnosis of bradykinin-dependent angioedema. PLoS One. 2013;8(8):e70140. PubMed PMID: 23940538; PubMed Central PMCID: PMCPMC3734293.
   PubMed Web of Science ®Google Scholar
• Germenis AE, Margaglione M, Pesquero JB, et al. International consensus on the use of genetics in the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2019 Oct 24. DOI:10.1016/j.jaip.2019.10.004. [ PubMed PMID: 31669336].
   PubMedGoogle Scholar
• HAE global registry. [cited 2019 Oct 15]. Available from: https://it.hae.cloud-r.eu
   Google Scholar
• Doshi BS, Arruda VR. Gene therapy for hemophilia: what does the future hold? Ther Adv Hematol. 2018 Sep;9(9):273–293. PubMed PMID: 30210756; PubMed Central PMCID: PMCPMC6130099.
   PubMed Web of Science ®Google Scholar